Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bruce Friedman

Critical Care Medicine Augusta, GA Medical Doctor

NPI 1417939315 CMS profile 290650

3651 Wheeler Rd, Burn Center, Augusta, GA 30909

Open in the dashboard

General payments

$629,289

649 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$23,650 paid to institutions, not to them · program years 2022–2023

Through program year 2025, Bruce Friedman of Augusta, GA is reported in the CMS Open Payments database as having received $629,289 across 649 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $23,650 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31,627 34
2024 General $21,044 13
2023 General $95,104 76
2022 General $126,179 112
2021 General $88,201 74
2020 General $45,895 76
2019 General $221,239 264

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bruce Friedman
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Bruce Friedman were reported at $31,627. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Bruce Friedman Critical Care Medicine median Middle half National median
2019 $221,239 $149 $51–$535 $163
2020 $45,895 $110 $30–$325 $114
2021 $88,201 $125 $34–$403 $132
2022 $126,179 $157 $49–$582 $149
2023 $95,104 $162 $56–$621 $160
2024 $21,044 $168 $53–$634 $164
2025 $31,627 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Shionogi Inc $172,168 147 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $115,095 103 payments
  3. AcelRx Pharmaceuticals, Inc. $60,476 80 payments
  4. La Jolla Pharmaceutical Company $58,253 32 payments
  5. Portola Pharmaceuticals, Inc. $53,912 60 payments
  6. Paratek Pharmaceuticals, Inc. $46,678 55 payments
  7. Melinta Therapeutics, Inc. $28,046 39 payments
  8. Merck Sharp & Dohme Corporation $22,083 41 payments
  9. Astellas Pharma US Inc $16,226 15 payments
  10. Medline Industries, Inc. $13,949 11 payments
  11. Other $42,404 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $156,345 56 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $153,643 37 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $125,804 58 payments
  4. Travel and Lodging $96,732 259 payments
  5. Consulting Fee $47,381 25 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $35,650 14 payments
  7. Food and Beverage $13,710 198 payments
  8. Education $25 2 payments
Products named General payments · program years 2019–2025
  1. Fetroja $167,070 135 payments
  2. RELISTOR $108,639 96 payments
  3. DSUVIA $60,476 80 payments
  4. ANDEXXA $53,912 60 payments
  5. NUZYRA $46,678 55 payments
  6. GIAPREZA $31,429 16 payments
  7. Vabomere $27,321 32 payments
  8. XERAVA $15,621 5 payments
  9. ZERBAXA $15,391 28 payments
  10. Dermatology and Wound Care $13,671 8 payments
  11. Other $65,876 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$42,714

Medicare's payments for the services billed

Medicare patients

54

Average age 65

Services billed

384

19 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 54%
Chronic kidney disease 52%
Heart failure 50%
Arthritis 48%
Depression 41%
Ischemic heart disease 35%
Atrial fibrillation 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Fetroja
  • Shionogi Inc $20,369
$20,369 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

649 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record